423 related articles for article (PubMed ID: 32541321)
21. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
Kerr DA; Brcic I; Diaz-Perez JA; Shih A; Wilky BA; Pretell-Mazzini J; Subhawong TK; Nielsen GP; Rosenberg AE
Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
23. Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy.
Toda Y; Ishihara S; Kawai A; Yoshida A
Virchows Arch; 2023 Jul; 483(1):125-129. PubMed ID: 36447097
[TBL] [Abstract][Full Text] [Related]
24. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
[TBL] [Abstract][Full Text] [Related]
25. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
[TBL] [Abstract][Full Text] [Related]
27. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
29. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
[TBL] [Abstract][Full Text] [Related]
30. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
31. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
32. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
[TBL] [Abstract][Full Text] [Related]
33. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
34. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
35. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
36. Metastatic giant cell tumour of bone: a narrative review of management options and approaches.
Xu R; Choong PFM
ANZ J Surg; 2022 Apr; 92(4):691-696. PubMed ID: 35143093
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone.
Kanwat H; Banjara R; Kumar VS; Majeed A; Gamnagatti S; Khan SA
J Orthop Surg (Hong Kong); 2021; 29(2):23094990211007565. PubMed ID: 34231432
[TBL] [Abstract][Full Text] [Related]
38. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
39. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
40. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Ciani G; Righi A; Akahane M; Honoki K; Tanaka Y; Donati DM; Errani C
Orthopedics; 2020 Sep; 43(5):284-291. PubMed ID: 32745221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
